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Abstract
Background: Defective epithelial repair, excess fibroblasts and myofibroblasts, collagen overproduction and fibrosis
occur in a number of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and
pulmonary fibrosis. Pathological conversion of epithelial cells into fibroblasts (epithelial-mesenchymal transition,
EMT) has been proposed as a mechanism for the increased fibroblast numbers and has been demonstrated to
occur in lung alveolar epithelial cells. Whether other airway cell types also have the capability to undergo EMT has
been less explored so far. A better understanding of the full extent of EMT in airways, and the underlying
mechanisms, can provide important insights into airway disease pathology and enable the development of new
therapies. The main aim of this study was to test whether primary human bronchial epithelial cells are able to
undergo EMT in vitro and to investigate the effect of various profibrotic factors in the process.
Results: Our data demonstrate that primary human bronchial epithelial cells (HBECs) are able to undergo EMT in
response to transforming growth factor-beta 1 (TGF-b1), as revealed by typical morphological alterations and EMT
marker progression at the RNA level by real-time quantitative polymerase chain reaction and, at the protein level,
by western blot. By using pharmacological inhibitors we show that this is a Smad-dependent mechanism and is
independent of extracellular signal-related kinase pathway activation. Additional cytokines and growth factors such
as tumour necrosis factor-alpha (TNF-a), interleukin-1 beta (IL1b) and connective tissue growth factor (CTGF) were
also tested, alone or in combination with TGF-b1. TNF-a markedly enhances the effect of TGF-b1 on EMT, whereas
IL1b shows only a very weak effect and CTGF has no significant effect. We have also found that cell-matrix contact,
in particular to fibronectin, an ECM component upregulated in fibrotic lesions, potentiates EMT in both human
alveolar epithelial cells and HBECs. Furthermore, we also show that the collagen discoidin domain receptor 1
(DDR1), generally expressed in epithelial cells, is downregulated during the EMT of bronchial epithelium whereas
DDR2 is unaffected. Our results also suggest that bone morphogenetic protein-4 is likely to have a context
dependent effect during the EMT of HBECs, being able to induce the expression of EMT markers and, at the same
time, to inhibit TGF-b induced epithelial transdifferentiation.
Conclusions: The results presented in this study provide additional insights into EMT, a potentially very important
mechanism in fibrogenesis. We show that, in addition to alveolar epithelial type II cells, primary HBECs are also able
to undergo EMT in vitro upon TGF-b1 stimulation via a primarily Smad 2/3 dependent mechanism. The effect of
TGF-b1 is potentiated on fibronectin matrix and in the presence of TNF-a, representing a millieu reminiscent of
fibrotic lesions. Our results can contribute to a better understanding of lung fibrosis and to the development of
new therapeutic approaches.
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Epithelial-mesenchymal transition (EMT) is the trans-
differentiation of epithelial cells into mesenchymal cells.
During this process, epithelial cells are removed of cellu-
lar polarity and epithelial cell-cell, as well as cell-matrix
adhesion contacts are remodelled. Markers of polarized
epithelial cells, such as E-cadherin and some cytokera-
tins, are lost whereas markers of mesenchymal cells
such as vimentin, N-cadherin or of myofibroblasts, as a-
smooth muscle actin (a-SMA) are acquired [1]. As a
result of these changes, epithelial cells are converted
into motile fibroblasts to myofibroblasts (FMT) that are
key cells in both the degradation and de novo synthesis
of the extracellular matrix (ECM). The trans-differen-
tiated cells are able to migrate through basement mem-
branes into other areas in the tissue. EMT has been
shown to play a role in organogenesis during embryonic
development and is an important biological process in
normal wound healing [2]. However, disregulated EMT
also appears to occur in disease, contributing to cancer
progression and metastasis, as well as to the pathogen-
esis of chronic degenerative fibrotic disorders in several
organs including the lung [3,4].
Dysfunction of the lungs and conducting airways at dif-
ferent levels may lead to a number of respiratory diseases
such as asthma, cystic fibrosis, chronic obstructive pul-
monary disease (COPD) and pulmonary fibrosis and an
important role for EMT has been proposed in the patho-
genesis of many of these [5-8]. Particularly, recent studies
have identified important mechanisms that control the
mesenchymal trans-differentiation of lung alveolar epithe-
lial cells (AECs) in pulmonary fibrosis. It has been shown
that both rat and human lung AECs can undergo EMT in
response to exposure to transforming growth factor
(TGF)-b1 in culture [9-11]. The EMT of alveolar cells was
later demonstrated in vivo by generating transgenic mice
expressing b-galactosidase exclusively in lung epithelial
cells and following their fate after inducing lung fibrosis by
intranasal instillation of adenoviral TGF-b1 [12]. Further
evidence for the re-occurence of EMT in adult tissue, as
well as for its possible role in pathogenesis, was obtained
from lung tissue from idiopathic pulmonary fibrosis (IPF)
patients by co-localization of myofibroblast and epithelial
markers in AECs overlying fibroblastic foci, which are key
features of the disease and are important for both diagno-
sis and disease progression [11].
A number of growth factors and cytokines are able to
induce EMT in vitro.T G F - b is a central regulator of
pulmonary inflammation and fibrosis [13]. TGF-b1h a s
been reported to induce EMT in AECs as well as the
differentiation of fibroblasts to myofibroblasts and was
also shown to be upregulated in IPF patients [11,14-16].
Several other factors have also been identified that
appear to act in concert with or to modulate TGF-b
activity. Whereas on its own IL (interleukin)1b does not
induce EMT in A549 cells and similarly, tumour necro-
sis factor (TNF)-a has only a mild effect, when com-
bined with TGF-b the two factors enhance EMT in type
II AECs in both rat-derived cells and in the human
A549 cell line. Similarly, connective tissue growth factor
(CTGF) is produced by fibroblasts and bronchial epithe-
lial cells and is also known to regulate fibroblast prolif-
eration and collagen deposition in coordination with
TGF-b [17,18].
The molecular mechanisms underlying EMT in the
lung have not been explored in great detail. TGF-b1i s
known to signal through two main pathways: the cano-
nical Smad-dependent pathway and the alternative mito-
gen-activated protein kinase (MAPK) pathway [19]. Both
of these have been implicated in EMT and FMT
[7,20-22]. In addition, bone morphogenetic proteins
(BMPs), members of the TGF-b superfamily, are
involved in a variety of biological functions including
lung morphogenesis [23]. The balance and interplay
between BMP and TGF-b signalling has been demon-
strated to be important to development [24]. Smad2 and
Smad3 are activated by activin receptor-like kinase
(ALK)-4, -5 and -7 receptors in response to TGF-b
ligands, whereas Smad1, Smad5 and Smad8 are activated
by ALK-1, -2, -3 and -6 in response to BMPs [25]. Sev-
eral BMPs, particularly BMP7 and BMP4, have been
implicated in EMT in various organs such as the kidney
and lung [26,27].
The ECM also appears to be playing key roles in
fibrosis not only as a major cause of the disruption of
tissue architecture but also due to its ability to activate
cellular pathways. The main ECM components of lung
basement membranes are collagen IV and laminin [28].
For example, in IPF lung basement membranes are dis-
rupted and the expression of collagen I, collagen III and
fibronectin is upregulated [29-31]. Furthermore, fibro-
nectin has been recently shown to drive the EMT of
mouse AECII [12]. Two main families of receptors for
ECM proteins have been implicated in lung cancer and
fibrosis [32]: integrins and the discoidin domain recep-
tors (DDRs). While integrins can sense various ECM
proteins, DDRs appear to play a more specialized role.
They are receptor tyrosine kinases that function as col-
lagen receptors and have intrinsic signalling properties
[33]. DDR1 is expressed primarily in epithelial tissues,
whereas the other member of the subfamily, DDR2, is
mostly present in mesenchymal cells [34]. The differen-
tial expression of DDR receptors appears to be context
and disease dependent. Human nasopharyngeal carci-
noma and HAK-1B hepatoma cells showed overexpres-
sion of DDR2, whereas DDR1 expression was unaltered
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was upregulated, whereas DDR2 expression was unaf-
fected [37]. As collagen receptors, DDRs may play a role
in mechanisms related to excessive collagen deposition,
such as EMT or FMT in fibrosis. However, they have
not yet been explored in this context.
Another mechanism that is proposed to contribute to
the remodelling of diseases is the disturbed physiological
balance between matrix formation and degradation. This
equilibrium appears to be lost in fibrotic diseases and
several matrix metalloproteases (MMPs), involved in
both matrix turnover and growth factor activation, such
as MMP-2 and MMP-9, have been shown to be upregu-
lated [38]. These two MMPs also play a role in the clea-
vage and activation of the main profibrotic growth
factor, TGF-b, and, hence, they may be of particular
importance [39].
The identification of the specific epithelial cell types
that are able to undergo EMT, and the underlying
mechanisms, has recently been a matter of intense
investigation as this may be an important process by
which fibroblast numbers increase, constituting the
fibroblastic foci correlated with severity of pulmonary
fibrosis [40]. As described above, most of the work on
lung EMT has focused on the alveolar epithelium. The
increased expression of the mesenchymal marker
S100A4 in airway epithelium biopsy samples from lung
transplant patients suggests that the epithelium lining
the conducting airways might also be able to differenti-
ate into mesenchymal cells [41]. In the current study,
we asked whether primary human bronchial epithelial
cells, similarly to AECs, can also undergo EMT. We
demonstrate that these cells can phenotypically convert
to mesenchymal cells, an effect potentiated in a patholo-
gical environment reminiscent of fibrotic disease com-
posed of TGF-b1 and fibronectin. Furthermore, we
show that this is a Smad-dependent mechanism and
implicate BMP4 and DDR1 in bronchial epithelial cell
transdifferentiation.
Materials and methods
Cell culture
A549 cells (ATCC) were maintained in DMEM (Invitro-
gen, CA, USA) supplemented with 10% fetal bovine
serum (FBS), 1% penicillin/streptomycin and human
bronchial epithelial cells (HBECs; Lonza, Basel, Switzer-
land) were maintained in BEGM medium (Lonza), both
at 37°C in the presence of 5% CO2 in a humidified incu-
bator. Except for the experiments shown in Figure 1, all
further experiments with HBECs were performed in
BEGM medium only, unless indicated otherwise.
EMT assay
A549 cells were seeded at a density of 6 × 10
4 cells/well
(12-well plates) in DMEM 1% FBS and HBECs at a
density of 10
6 cells/well in 1:100 BEGM:BEBM (six-well
plates). Cells were allowed to adhere for 1 day and then
changed into media containing 5 ng/ml of TGF-b1
(R&D Systems, MN, USA). A549 cells were differen-
tiated for 48 h and HBECs for 3-5 days. Human BMP4
recombinant protein (5 or 50 ng/ml, R&D Systems) was
used in some EMT experiments.
EMT assay in the presence of pharmacological inhibitors
A549 and HBECs were incubated with pharmacological
inhibitors for 1 h prior to the addition of TGF-b1
(5 ng/ml) for EMT induction for 48 h or 3-5 days,
respectively (see legends for Figures 1,2,3,4,5 for further
description). The Smad pathway inhibitor SB431542 (10
μM, Sigma-Aldrich) and the ERK pathway inhibitor
PD98059 (10 μM, Calbiochem) were used.
Western blotting
Cells were lysed in a buffer containing 1% NP-40, 150
mM NaCl, 50 mM Tris pH 8.0, 1 mM sodium orthova-
nadate, 5 mM NaF and protease inhibitor cocktail
(Sigma, NY, USA). Lysates were subjected to SDS-
PAGE on a 4-10% Bis-Tris gels (NuPAGE, Invitrogen).
They were then transferred onto nitrocellulose mem-
branes (Invitrogen) and blocked in Tris-buffered saline
(TBS), 0.1% Tween-20, 5% non-fat dried milk for 1 h at
room temperature (RT). The blots were then washed
three times in TBS 0.1% Tween (TBS-T) and incubated
for 1 h at RT with a horseradish peroxidase-labelled
secondary antibody (Invitrogen). After repeated washing
in TBS-T the immunoreactive proteins were detected
by chemiluminescence (ECL; Pierce, L, USA) according
to the manufacturer’s instructions. The following anti-
bodies were used: E-cadherin (Abcam, MA, USA),
N-cadherin (Zymed, CA, USA), vimentin (Abcam), a-
SMA (Sigma), MMP-2 (R&D Systems), pSmad2 (Cell
Signaling, MA, USA), pSmad1/5/8 (Cell Signaling),
DDR1 (R&D Systems), glyceraldehyde 3-phosphate
dehydrogenase (GAPDH; Santa Cruz Biotechnology,
CA, USA).
Real-time quantitative polymerase chain reaction (PCR)
Total RNA was prepared from cells using the RNeasy
plus mini kit (Qiagen), according to manufacturer’s
instructions and RNA was reverse transcribedinto
cDNA (Applied Biosystems, CA, USA). The cDNA was
then amplified by real-time quantitative TaqMan PCR in
a reaction containing 1× Taqman Universal PCR master
mix, 1 μM primers, 0.3 μM probe and analysed using an
ABI Prism 7900 sequence detector (Applied Biosystems).
The house-keeping gene GAPDH was used as internal
control. Data were normalized to GAPDH and
expressed as fold change over control (Table 1).
Statistical analysis
The data show the mean ± standard deviation of at least
three independent experiments (n = 3), unless otherwise
indicated. Statistical significance was determined using
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was performed using GraphPad Prism software.
Results
TGF-b1 induces EMT in HBECs
In order to address the question of whether EMT can
occur in AECs we first stimulated HBECs with TGF-b1
for 3-5 days. We observed a dramatic upregulation of
collagen I mRNA expression and downregulation of the
epithelial marker E-cad, as well as an enhanced expres-
sion of the metalloprotease MMP-2 after EMT induc-
tion (Figure 1a). Similarly, an increased expression of
several mesenchymal markers including N-cad, vimen-
tin, MMP-2 and of the myofibroblast marker a-SMA
was detected at the protein level (Figure 1b). In contrast,
a reduced expression of E-cad was observed in the pre-
sence of TGF-b1 (Figure 1b). We concluded from these
data that TGF-b1 induces EMT in HBECs as revealed
by a downregulation of epithelial markers and an upre-
gulation of mesenchymal markers at both the RNA and
the protein level. A concomitant upregulation of phos-
pho-Smad2 with EMT induction in HBECs prompted us
to investigate which signaling pathways were involved in
this phenomenon.
Smad inhibition prevents TGF-b1 induction of EMT in
HBECs
In order to determine which of two main pathways, the
Smad-dependent pathway or MAPK/ERK1/2 pathway -
both of which can be activated by TGF-b, were involved
in EMT in HBECs, we treated cells with pharmacologi-
cal inhibitors for each pathway prior to the induction of
EMT by TGF-b1. For the inhibition of the Smad path-
way, we used SB431542, a potent and specific inhibitor
of TGF-b type I receptor kinases (ALK-4,-5,-7), there-
fore an inhibitor of TGF-b signalling with no effect on
ALK-1,-2,-3 and -6 and, hence, BMP signalling [42]. We
found that treatment of HBECs with SB431542 before
the addition of TGF-b1 prevented EMT, as demon-
strated by the unchanged expression of marker proteins
and their mRNA (Figure 2b and 2d) as well as by the
preserved cellular morphology (Figure 2a). In contrast,
the MEK/ERK inhibitor PD98059 failed to fully inhibit
EMT (Figure 2a and 2b). Taken together, these results
show that HBECs can undergo EMT in vitro in response
to TGF-b1 via a primarily Smad-dependent mechanism.
BMP4 is involved in EMT in HBECs
Two BMPs, BMP7 and BMP4, have so far been impli-
cated in EMT in various organs. BMP7, and not BMP4,
Figure 1 Transforming growth factor (TGF)-b1 induces epithelial mesenchymal transition (EMT) in human bronchial epithelial cells
(HBECs). HBECs were incubated with TGF-b1 (5 ng/ml) for 72 h in order to induce EMT. (a) Quantitative polymerase chain reaction analysis
shows that TGF-b1 induces the mRNA expression of collagen I a 1 and matrix metalloprotease (MMP)2 and downregulates the epithelial marker
E-cad. The relative expression level of each gene was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA in the same
sample. Statistical significance was determined by Student’s t test; *P < 0.05, **P < 0.01, ***P < 0.001. (b) Western-blot analysis shows that TGF-b1
induces an upregulation of mesenchymal proteins (N-cad, vimentin, MMP-2) and of the myofibroblast protein a-smooth muscle actin and a
downregulation of the epithelial marker E-cad in two different culture media. It also reveals an upregulation of phosho-Smad2 with TGF-b1
stimulation. An antibody against GAPDH was used as loading control. All further experiments were performed in the presence of BEGM medium
unless indicated otherwise.
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(HBECs) is Smad-dependent. HBECs that have been pre-incubated with the activin receptor-like kinase (ALK)-5 inhibitor SB431542 (SB, 10 μM)
1 h before the addition of TGF-b1 (5 ng/ml) are unable to undergo EMT after 5 days of differentiation. By contrast, mitogen-activated protein
kinase inhibition by PD98059, a MEK inhibitor (PD, 10 μM), only partially inhibits EMT. (a) Representative phase contrast images (10×
magnification, scale bar = 10 μM) show that HBECs in the presence of TGF-b1 lose cell-cell contact, become more sparse and change into an
elongated fibroblastoid morphology. This effect is inhibited after pre-incubation of the cells with the ALK-4,-5,-7 inhibitor SB but not by the MEK
inhibitor PD. (b) Western-blot analysis shows that SB completely abolishes TGF-b1 gene regulation of E-cad and the phosho-Smad2 signal is fully
inhibited in the presence of SB. An antibody against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. (c)
Western-blot analysis shows that the upregulation of matrix metalloprotease (MMP)-2 by TGF-b1 is partially inhibited by the presence of bone
morphogenetic proteins (BMP)4 confirming the quantitative polymerase chain reaction (qPCR) results shown in (d). Phosho-Smad1/5/8 shows
active BMP signalling in the presence of BMP4 which is inhibited in the presence of TGF-b1. An antibody against GAPDH was used as loading
control. (d) q(PCR) analysis shows that SB inhibits gene expression changes of collagen I a 1, MMP2, MMP-9 and E-cad induced by TGF-b1 (top 2
panels). BMP4 (50 ng/ml) induces a significant upregulation of collagen I in the presence of TGF-b1, as compared to TGF-b1 alone (top left
panel) and has no significant effect on E-cad expression either alone or in combination with TGF-b1 (top right panel). In contrast, the
upregulation of MMP-2 and MMP-9 expression in the presence of TGF-b1 is significantly inhibited by concomitant BMP4 treatment (bottom 2
panels). The relative expression level of each gene was normalized to GAPDH mRNA in the same sample. Statistical significance was determined
by one-way ANOVA followed by Tukey test; ***P < 0.001.
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the kidney and to induce mesenchymal to epithelial
transition [27,43]. However, the evidence for the impor-
tance of BMP7 in the lung is less convincing, as BMP7
does not appear to inhibit EMT in vitro in A549s or in
vivo in the bleomycin model [44]. Similarly, previous
data on the role of BMP4 in EMT in the lung is rather
conflicting. Whereas BMP4 was shown to induce EMT
in the BEAS2B epithelial cell line, overexpressing Grem-
lin, an inhibitor of BMP4 signalling, also appeared to
enhance EMT in A549 cells [26,45].
In order to determine whether BMP4 may also play a
role in fibrosis pathogenesis of the airways via modulat-
ing EMT in HBECs, we incubated human BMP4 recom-
binant protein alone or before inducing EMT with
TGF-b1 in HBECs. We found that BMP4 enhanced col-
lagen I mRNA expression in the presence of TGF-b1
(Figure 2d). In contrast, the mRNA over expression of
the metalloproteases MMP-2 and MMP-9 induced by
TGF-b1 was inhibited by BMP4 (Figure 2d). An antago-
nistic effect of the BMP4 protein upon the TGF-b1-
mediated upregulation of MMP2 protein was also
confirmed by western blot (Figure 2c) and by assessing
cellular morphology using phase contrast microscopy
(data not shown). In order to assure that BMP signalling
was active in the presence of BMP4 recombinant pro-
t e i n ,w eu s e da na n t i b o d yt h a tc r o s s - r e a c t sw i t ht h e
phosphorylated forms of Smads 1, 5 and 8, downstream
effectors of BMP signalling. We found increased phos-
phorylation of Smad1/5/8 in the presence of both low (5
ng/ml) and high (50 ng/ml) concentrations of human
BMP4 recombinant protein, an effect that could be
abrogated if TGF-b1 was concomitantly added (Figure
2c). These results suggest a possible interplay between
the BMP and TGFb pathways during EMT in HBECs.
TNF-a enhances the effect of TGF-b1 on EMT induction in
HBECs
Next, we asked whether other cytokines and growth fac-
tors previously implicated in interstitial lung disease,
such as TNF-a,I L 1 b and CTGF [46,47], alone or in
combination with TGF-b1, would induce or alter the
progression of EMT in HBECs. While TGF-b1i s
involved in several biological processes and in EMT in
many developmental and pathological scenarios, other
Figure 3 Tumour necrosis factor (TNF)-a enhances the effect of transforming growth factor (TGF)-b1 on epithelial mesenchymal
transition (EMT) induction in human bronchial epithelial cells (HBECs). (a) Western-blot analysis shows that TNF-a further potentiates the
upregulation of N-cad and matrix metalloprotease (MMP)-2 and a downregulation of E-cad induced by TGF-b1. TNF-a, itself or in combination
with TGF-b1 also induces Smad2 phosphorylation. An antibody against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as
loading control. (b) Quantitative polymerase chain reaction analysis shows that TNF-a, when in combination with TGF-b1, induces a dramatic
increase in MMP-2 and MMP-9 mRNA expression. Furthermore, TNF-a treatment alone reduces E-cad expression by approximately 50% whereas
IL-1b or connective tissue growth factor have no effect on their own, neither do they potentiate TGF-b1 induced gene expression changes. The
relative expression level of each gene was normalized to GAPDH mRNA in the same sample. Statistical significance was determined by one-way
ANOVA followed by Tukey test; ***P < 0.001
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ferring context specificity. Indeed, we found that TNF-a
markedly enhanced the effect of TGF-b1o nE M T ,
whereas IL1b appeared to have a weak effect on MMP-9
expression but not on the expression of MMP-2 or Ecad
(Figure 3a and 3b). Interestingly, CTGF, a profibrotic
growth factor and a downstream effector of TGF-b sig-
nalling, had no significant effect when added alone or in
combination with TGF-b1.
Disease associated matrix enhances EMT in HBECs
In order to investigate if, in addition to soluble factors,
cell-matrix contact would also modulate EMT in human
airway epithelial cells we tested the effect of ECM com-
ponents that have been associated with fibrotic lesions
in IPF. Initially we tested whether type II A549 cells
were affected by fibronectin and we found that alone it
significantly upregulated mRNA expression of two
important EMT markers, collagen I and MMP-2 (Figure
4a). Similarly, at the protein level, we detected signifi-
cant induction of the mesenchymal markers N-cad and
vimentin and the downregulation of the epithelial mar-
ker E-cad when cells were grown on fibronectin com-
pared to cells grown on control plates coated with poly-
D-lysine (PDL; Figure 4b).
We next looked to see if cellular contact with the
fibronectin observed in AECII cells could also contri-
bute to the progression of EMT in HBECs. In contrast
to what we observed in alveolar type II epithelial cells,
fibronectin on its own did not seem to have a significant
effect on EMT in HBECs. Remarkably, however, when
applied in combination with TGF-b1, fibronectin signifi-
cantly enhanced TGF-b1-induced EMT in HBECs, as
demonstrated by both the induction of mesenchymal
and the downregulation of epithelial markers (Figure 4c
and 4d).
The collagen receptor DDR1 is downregulated in
bronchial epithelial cells during EMT
Since the collagen receptors, DDRs, have been asso-
ciated with remodelling and fibroproliferative diseases,
we addressed the question of whether DDR expression
Figure 4 Fibronectin promotes epithelial mesenchymal transition (EMT) in A549 cells and enhances transforming growth factor (TGF)-
b1-induced EMT in human bronchial epithelial cells (HBECs). Human epithelial cells, either alveolar type II A549s (a and b) or primary
human bronchial cells (c and d) were plated at equal cell density on PDL or fibronectin-coated dishes and EMT assays performed as described in
Materials and Methods. (a and c) Quantitative polymerase chain reaction analysis shows a significant upregulation of collagen I and matrix
metalloprotease-2 in A549 cells (a) and HBECs (c) grown on fibronectin compared to PDL in A. In the presence of TGF-b1, fibronectin shows a
further significant upregulation of these EMT markers when compared to cells grown on PDL in both cell types. Statistical significance was
determined by one-way ANOVA followed by Tukey test; *P < 0.05, **P < 0.01, ***P < 0.001. (b and d) Western-blot analysis shows upregulation
of mesenchymal marker proteins and downregulation of epithelial marker proteins in cells on fibronectin as compared to control cells on PDL
for both A549 cells (b) and HBECs (d). An antibody against GAPDH was used as loading control.
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Although no DDR expression changes were detected in
A549 epithelial cells during EMT (data not shown),
DDR1 was consistently downregulated in HBECs at
both the RNA and the protein level during TGF-b1-
induced EMT (Figure 5a and 5b). In contrast, the other
discoidin domain collagen receptor DDR2 expression
did not show significant changes under any of the con-
ditions tested.
Discussion
The majority of the work on EMT in pulmonary fibrosis
has so far been focused on AECs and it is less clear
whether bronchial epithelial cells are able to undergo
EMT. Further understanding of the EMT mechanisms
in fibrosis is potentially of great importance as it could
lead to approaches which impede or reverse the increase
in the number of fibroblasts in fibrotic diseases.
Our work reveals that, in addition to AECII, primary
HBECs are also able to convert to mesenchymal pheno-
types in a Smad-dependent manner. While this work
was in progress, other studies have recently also
reported EMT in human airway epithelial cells. Zhang
and colleagues have reported EMT-related changes in
the polarized layer forming airway epithelial cell line
16HBE-14o [48] and our study extends these findings to
primary HBECs. Borthwick and colleagues also support
these findings [49]. In their study they demonstrated
Figure 5 Discoidin domain receptor (DDR)1 expression is downregulated in human bronchial epithelial cells (HBECs) following
epithelial mesenchymal transition (EMT) whereas DDR2 expression is unaltered. (a) Quantitative polymerase chain reaction analysis shows
a 35% and 50% reduction of DDR1 expression after transforming growth factor (TGF)-b1 stimulation for 5 days in HBECs on plastic and PDL,
respectively (top panel). However, DDR2 expression does not appear to change significantly in response to TGF-b1 treatment (bottom panel).
The relative expression level of DDRs was normalized to glyceraldehyde 3-phosphate dehydrogenase mRNA in the same sample. Statistical
significance was determined by one-way ANOVA followed by Tukey test; **P < 0.01, ***P < 0.001. (b) Western-blot analysis confirms a reduction
of DDR1 protein expression level upon TGF-b1 treatment in HBECs in two different media.
Table 1 Sequences used for real-time quantitative polymerase chain reaction
Gene Forward primer (5’-3’) Reverse primer (5’-3’) Probe
Collagen I TGGCCTCGGAGGAAACTTT TCCGGTTGATTTCTCATCATAGC CCCCAGCTGTCTTAT
MMP-2 CGTCTGTCCCAGGATGACATC TGTCAGGAGAGGCCCCATAG 6FAM-AGGGCATTCAGGAGC
MMP-9 TGGGCAGATTCCAAACCTTT TCTTCCGAGTAGTTTTGGATCCA 6-FAM-CCACCACAACATCACCTA
E-cadherin Pre-mixed primers and probe (Applied Biosystems, CA, USA)
GAPDH Pre-mixed primers and probe (Applied Biosystems)
MMP, matrix metalloprotease; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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cell marker expression in the epthelial cells in biopsies
from obliterative bronchiolitis patients using immuno-
histochemistry. Furthermore, in a very recent study, air-
way epithelial cells isolated from asthmatics have been
shown to be sensitized to TGF-b induced EMT [50].
These studies and our present work together provide
supportive evidence for the occurence of EMT in airway
epithelium in addition to the more extensively described
process in the alveoli. Interestingly, it has been very
recently reported that mouse tracheal epithelial cells can
be induced to undergo EMT with TGF-b1 in vitro [51].
Whether this is the case with human tracheal cells
remains to be determined. Nevertheless, a number of
specialized airway and lung epithelial cell types appear
to maintain an intrinsic plasticity that allows them to
transdifferentiate into mesenchymal cells in pathological
settings.
Our results also demonstrate that fibronectin alone is
able to promote EMT in A549 epithelial cells and there-
fore extends the findings of Kim et al.[ 1 2 ]t ot h e
human setting, confirming an important role for fibro-
nectin in the induction of EMT in human AECII. While
fibronectin alone shows no significant effect in HBECs,
EMT in these cells is potentiated in a pathological envir-
onment where fibronectin and excess TGF-b1c o - e x i s t ,
further strengthening the relevance of our findings in
disease.
Our study also gives new insight into some of the
mechanism of EMT in bronchial epithelial cells. We
show that DDR1 is downregulated during EMT in bron-
chial epithelium, whereas DDR2 is unaffected. Given
that DDR1 is mostly expressed by epithelial, and not
mesenchymal tissue, the reduction of its expression dur-
ing EMT correlates with a decrease in epithelial identity.
Remarkably, in a study comparing rat skin fetal fibro-
blasts of scar-free or scar-forming gestational ages,
DDR1 was found to be downregulated at stages where
scarring was no longer possible and collagen I was pro-
duced in excess. DDR2 levels were similar throughout
gestation [52]. An analogy can be drawn with fibrosis in
the adult where collagen I is overproduced and fibro-
blast numbers increase partly due to EMT and scarring
of the tissue occurs. It therefore seems that, in situations
of excess collagen and fibrosis, DDR1 can be downregu-
lated in epithelial cells. Our findings also support recent
reports on SLUG-induced EMT in Madin-Darby canine
kidney cells with reduced DDR1 expression when
induced to undergo EMT [53]. Shintani and colleagues
(2008) [54] showed that collagen I-mediated upregula-
tion of N-cadherin required cooperative signals from
DDR1 and integrin b1 in pancreatic cells. Since we and
others have shown that N-cadherin is upregulated in
bronchial EMT, it will be interesting to evaluate in
future studies whether integrins also play a role and
whether there is any interplay with DDR1 in EMT in
HBECs.
We have also investigated the effect of BMP4 during
EMT of primary HBECs. Our data suggest a possible
dual and context-dependent role for this growth factor.
While it induced morphological EMT-like changes in
HBECs, and was also able to upregulate collagen I
expression, our data demonstrate that when applied in
combination, BMP4 also inhibited TGF-b1-induced
epithelial cell differentiation as demonstrated by its
effect on MMP expression. Two epithelial cell lines
were previously shown to have opposite EMT responses
to BMP mediators. BEAS-2B, an airway epithelial cell
line, was induced to undergo EMT when exposed to
recombinant BMP4 [26,47]. On the other hand, the
A549 AEC cell line overexpressing the BMP inhibitor
Gremlin also showed enhanced EMT [26,47]. Further-
more, whereas Gremlin is over-expressed in the lungs of
IPF patients and the responsiveness of IPF fibroblasts to
BMP4 in culture is impaired, BMP4 and BMP7 activity
is not reduced in IPF biopsies or in asbestos-exposed
mouse lungs, as would be predicted by the increased
expression of the BMP inhibitor Gremlin in IPF [47,55].
The BMP4 induced mechanisms thus appear to be com-
plex as BMP4 activity can be modulated depending on
the cell type and the cytokine millieu. It is interesting to
speculate that the downregulation of MMPs, after BMP
treatment, may not be a direct EMT effect but a paralell
mechanism caused by the inhibitory effect of BMP sig-
nalling upon proteasome function [56]. In previous stu-
dies both MMP-2 and MMP-9 have been found to be
downregulated by proteasome inhibition and the protea-
some pathway has previously been linked to BMP sig-
nalling [56,57]. However, further studies are needed in
order to unravel the complexities of BMP-TGFb signal-
ling interactions in EMT in bronchial epithelium.
The induction of the expression of MMPs, including
MMP-2 and MMP-9 is well demonstrated in the context
of cancer metastasis and is purported to play a role in
both angiogenesis and cellular invasiveness [58] by con-
tributing to the enhanced migratory phenotype of the
cancer cell. Similarly, it was shown that, in in vitro
injury models of repairing HBECs, MMP-9 accumulated
in migrating HBECs at the leading edge of the wound
[59]. Given the dramatic increase of MMP-9 expression
that we have observed in HBECs undergoing EMT, it is
reasonable to speculate that HBECs also gain a migra-
tory phenotype during fibrosis pathogenesis in the lung.
Our planned investigations will address this intriguing
possibility in more detail.
Important recent advances demonstrate that several
lung epithelial cell types can undergo EMT in vitro and
suggest that the mechanism may also play a role in vivo
Câmara and Jarai Fibrogenesis Tissue Repair 2010, 3:2
http://www.fibrogenesis.com/content/3/1/2
Page 9 of 11during the development of various fibroproliferative dis-
eases. Recent data from two groups using different
detection methods demonstrated mesenchymal marker
expression in airway epithelial cells of lung transplant
patients with bronchiolitis obliterans [48,60]. Neverthe-
less, it is yet to be shown conclusively that EMT of
bronchial epithelial cells plays a significant role in air-
way tissue remodelling and peri-bronchial fibrosis in the
pathogenesis of lung diseases.
Conclusions
Our results provide an additional insight into EMT, a
potentially very important mechanism in fibrogenesis.
We demonstrate that TGF-b1 can drive EMT in pri-
mary HBECs in vitro. We also show that this effect is
primarily mediated via a Smad 2/3 dependent mechan-
ism and is potentiated by cell-fibronectin interaction, in
t h ep r e s e n c eo fT N F - a, and can be further modulated
by BMP pathway activation with BMP4. The results pro-
vided in this study establish the basis of future investiga-
tions into the mechanism of bronchial epithelial cell to
mesenchymal cell differentiation, which, in turn, can
contribute to a better understanding of lung fibrosis and
to the development of new therapeutic approaches.
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